Effect of epigenetic modifier-based combinations on efficacy in patients with peripheral T-cell lymphoma (PTCL): Deciphering impact of mutations in epigenetic operations on response.
O'Connor O, Sokol L, Shustov A, Falchi L, Lue J, Montanari F, Amengual J, Sawas A, Deng C, Khan K, Jacobs A, Rada A, Kim H, Soderquist C, Park D, Menezes D. Effect of epigenetic modifier-based combinations on efficacy in patients with peripheral T-cell lymphoma (PTCL): Deciphering impact of mutations in epigenetic operations on response. Journal Of Clinical Oncology 2019, 37: 7565-7565. DOI: 10.1200/jco.2019.37.15_suppl.7565.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaHistone deacetylase inhibitorsPTCL patientsNext-generation sequencingTET2 mutationsPhase 2 studyMajority of patientsPhase 1 studyTreatment-naïve individualsT-cell lymphomaLikelihood of responseClinical trial scenariosR lymphomaTCL patientsExploratory endpointsPreclinical dataEfficacy dataHypomethylating agentR StudyPatientsDeacetylase inhibitorsClinical metricsMarked activityLymphomaEpigenetic drugs